Affiliation:
1. Transplant Pharmacokinetic Laboratory, Dumont-UCLA Transplant Center, 10833 LeConte Avenue, Room 77-120, Los Angeles, CA 90025
Abstract
Since the early 1980s, the combination of cyclosporine, azathioprine, and prednisone has been the mainstay tripledrug immunosuppressive regimen used in transplantation. However, advances in drug research, design, and development have allowed for the introduction of new agents that have greatly increased the number of immunosuppressive agents available for use in transplant recipients. Particularly, the newer antiproliferative immunosuppressive drugs (agents that directly inhibit the proliferation of T and B lymphocytes) have had an important impact on patient outcomes posttransplant. These agents are mycophenolate mofetil and sirolimus.
Reference122 articles.
1. 1. Allison AC, Hovi T, Watts RWE, Webster ADB. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet. 1975;2:1179-1182.
2. 2. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067-1069.
3. 3. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties [abstract]. Nature. 1969;23:848-850.
4. 4. Allison AC, Eugui EM. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol. 1993;14:353-380.
5. The inhibition of nucleic acid synthesis by mycophenolic acid